Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774625 | 0.96 | USP30 (0.49) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774475 | 0.90 | USP30 (0.46) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774426 | 0.90 | CYP11B2 (0.48) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774532 | 0.90 | USP30 (0.46) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774411 | 0.89 | KDM1A (0.47) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774401 | 0.88 | CYP11B2 (0.44) | SLC22A12USP30UCHL1CYP11B2CYP11B1 | |
| SCHEMBL30774399 | 0.88 | CYP11B2 (0.51) | USP30UCHL1CYP11B2CYP11B1PDCD1 | |
| SCHEMBL31635535 | 0.88 | PDCD1 (0.44) | USP30UCHL1CYP11B2CYP11B1PDCD1 | |
| SCHEMBL30774430 | 0.88 | PDCD1 (0.44) | USP30UCHL1CYP11B2CYP11B1PDCD1 | |
| SCHEMBL30774528 | 0.87 | USP30 (0.43) | SLC22A12USP30UCHL1CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | SLC22A12 3869/4885USP30 728/4885UCHL1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.